



5-Aminosalicylate (5-ASA)

<https://libcat.nshealth.ca/en/permalink/chpams35397>

Available Online: View Pamphlet

Corporate Author: Nova Scotia Health Authority. Central Zone. Gastroenterology

Place of Publication: Halifax, NS

Publisher: Nova Scotia Health Authority

Date of Publication: 2016

Format: Pamphlet

Language: English

Physical Description: 1 electronic document (6 p.) : digital, PDF file

Subjects (MeSH): Inflammatory Bowel Diseases - drug therapy
Crohn Disease - drug therapy
Colitis - drug therapy

Subjects (LCSH): Inflammatory bowel diseases
Crohn's disease
Colitis

Abstract: 5-aminosalicylate (5-ASA) is a type of drug often used to treat inflammatory bowel disease (IBD). This type of drug is good at controlling active ulcerative colitis or Crohn's colitis as well as keeping ulcerative colitis in remission. Topics include: what 5-ASA type drugs do, which 5-ASA you should take, continuing to take the drug, talking to your doctor, what other medication you can take, and when to expect to see improvement. The pamphlet also describes common and rare side effects.

Responsibility: Prepared by: Jennifer Stewart, RN; Gastroenterology
Prepared by: Kaleigh MacIsaac, B.ScPharm; Gastroenterology
Revised by: Phyllis Durning, RN
Revised by: Alison Harding, B.Sc.

Pamphlet Number: 1483



Ustekinumab (Stelara) therapy for Crohn's disease

<https://libcat.nshealth.ca/en/permalink/chpams35722>

Available Online: View Pamphlet

Corporate Author: Nova Scotia Health Authority. QEII. Gastroenterology

Place of Publication: Halifax, NS

Publisher: Nova Scotia Health Authority

Date of Publication: 2017

Format: Pamphlet

Language: English

Physical Description: 1 electronic document (9 p.) : digital, PDF file

Subjects (MeSH): Ustekinumab
Crohn Disease - drug therapy

Subjects (LCSH): Crohn's disease
Gastrointestinal agents

Abstract: Your healthcare provider believes treatment with a medicine called ustekinumab (Stelara®) may help to manage your Crohn's disease. In this pamphlet you will find basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include: a brief description of the medicine, how it works, how it is given, precautions, side effects, symptoms to watch out for, pregnancy & breastfeeding, and other important things to know when undergoing this treatment.

Responsibility: Prepared by: Alison Harding BSc, Jennifer Stewart RN, CCRP, Dr. Des Leddin; Gastroenterology

Pamphlet Number: 1695



Vedolizumab (Entyvio) therapy

<https://libcat.nshealth.ca/en/permalink/chpams35620>

Available Online: View Pamphlet

Corporate Author: Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program

Place of Publication: Halifax, NS

Publisher: Nova Scotia Health Authority

Date of Publication: 2022

Format: Pamphlet

Language: English

Physical Description: 1 electronic document (11 p.) : digital, PDF file

Subjects (MeSH): Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy

Subjects (LCSH): Gastrointestinal agents
Ulcerative colitis
Crohn's disease

Specialty: Medications

Abstract: Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.

Responsibility: Prepared by: Nova Scotia Collaborative IBD Program

Pamphlet Number: 1623